Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (66.7%)
N/A1 (33.3%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
unknown

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

NCT01861834
completednot_applicable

Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease

NCT01284049
completedphase_4

Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease

NCT02349594
unknownphase_4

Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.

NCT00172198

Clinical Trials (4)

Showing 4 of 4 trials
NCT01861834

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

Unknown
NCT01284049Not Applicable

Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease

Completed
NCT02349594Phase 4

Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease

Completed
NCT00172198Phase 4

Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4